Evidence map›Paper›PMID 31848735›Full record

ArticleRheumatology international2020

Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis.

Edit Végh, György Kerekes, Anita Pusztai, Attila Hamar, Szilvia Szamosi, Andrea Váncsa, Levente Bodoki, Lilla Pogácsás, Fruzsina Balázs, Katalin Hodosi and 5 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Edit VéghDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
György KerekesDepartment of Angiology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.
Anita PusztaiDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
Attila HamarDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
Szilvia SzamosiDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
Andrea VáncsaDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
Levente BodokiDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
Lilla PogácsásDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
Fruzsina BalázsDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
Katalin HodosiDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
Andrea DomjánDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
Sándor SzántóDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
Zoltán NagyDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
Zoltán SzekaneczDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary. szekanecz.zoltan@med.unideb.hu.
Gabriella SzűcsDepartment of Rheumatology, Institute of Medicine, University of Debrecen, Faculty of Medicine, Nagyerdei str 98, Debrecen, 4032, Hungary.
University of Debrecen · HU

Funding

European Union GINOP-2.3.2-15-2016-00015European Union GINOP-2.3.2-15-2016-00050European Union TAMOP-4.2.4.A/2-11/1-2012-0001Pfizer Foundation WS1695414
6 · The paper itself

Abstract

Accelerated atherosclerosis, increased cardiovascular morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Vascular function, clinical and laboratory markers and the effects of anti-TNF therapy were assessed in arthritides. Fifty-three 53 patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and arterial pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment initiation. A significant improvement of brachial artery FMD was observed after 6 months (p = 0.004). A tendency of FMD improvement was also observed after 12 months (p = 0.065). ccIMT did not change throughout the year. PWV significantly improved after 12 months (p = 0.034). Higher baseline ccIMT (p = 0.009) and PWV (p = 0.038) were associated with clinical non-response (cNR) versus response (cR) to biologics. Multiple analysis confirmed the association of baseline ccIMT with age (p = 0.003) and cNR (p = 0.009), as well as that of baseline PWV with age at diagnosis (p = 0.022) and current chest pain (p = 0.004). Treatment itself determined the 12-month changes in FMD (p = 0.020) and PWV (p = 0.007). In a mixed cohort of RA and AS patients, TNF inhibition improved or stabilized vascular pathophysiology. Inflammation may be associated with FMD, while, among others, cNR may influence vascular function.

Indexed as

AdultAgedAged, 80 and overAntirheumatic AgentsArthritis, RheumatoidBrachial ArteryCarotid Intima-Media ThicknessCertolizumab PegolEndothelium, VascularEtanerceptFemaleFollow-Up StudiesHumansMaleMiddle AgedPulse Wave AnalysisAntirheumatic AgentsCertolizumab PegolEtanerceptAnkylosing spondylitisAtherosclerosisCardiovascular diseaseCarotid intima-media thicknessFlow-mediated vasodilationPulse-wave velocityRheumatoid arthritis

Identifiers

PMID31848735
OpenAlexW2994739191

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.